284 related articles for article (PubMed ID: 32073254)
1. Tafenoquine: A Step toward Malaria Elimination.
Lu KY; Derbyshire ER
Biochemistry; 2020 Mar; 59(8):911-920. PubMed ID: 32073254
[TBL] [Abstract][Full Text] [Related]
2. Tafenoquine: the new kid on the block.
Chen V; Daily JP
Curr Opin Infect Dis; 2019 Oct; 32(5):407-412. PubMed ID: 31305490
[TBL] [Abstract][Full Text] [Related]
3. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S; Rodrigo C; Fernando SD
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
5. Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.
Ebstie YA; Abay SM; Tadesse WT; Ejigu DA
Drug Des Devel Ther; 2016; 10():2387-99. PubMed ID: 27528800
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine: First Global Approval.
Frampton JE
Drugs; 2018 Sep; 78(14):1517-1523. PubMed ID: 30229442
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
[No Abstract] [Full Text] [Related]
8. Tafenoquine: a promising new antimalarial agent.
Crockett M; Kain KC
Expert Opin Investig Drugs; 2007 May; 16(5):705-15. PubMed ID: 17461742
[TBL] [Abstract][Full Text] [Related]
9. Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.
Maher SP; Vantaux A; Chaumeau V; Chua ACY; Cooper CA; Andolina C; Péneau J; Rouillier M; Rizopoulos Z; Phal S; Piv E; Vong C; Phen S; Chhin C; Tat B; Ouk S; Doeurk B; Kim S; Suriyakan S; Kittiphanakun P; Awuku NA; Conway AJ; Jiang RHY; Russell B; Bifani P; Campo B; Nosten F; Witkowski B; Kyle DE
Sci Rep; 2021 Oct; 11(1):19905. PubMed ID: 34620901
[TBL] [Abstract][Full Text] [Related]
10. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study).
Santos A; Brito M; Silva E; Rocha F; Oliveira A; Dávila R; Gama H; Albuquerque J; Paiva M; Baía-Silva D; Sampaio V; Balieiro P; Rufatto R; Grewal Daumerie P; Peterka C; Edilson Lima F; Monteiro W; Arcanjo A; Silva R; Batista Pereira D; Lacerda M; Murta F
PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012197. PubMed ID: 38837977
[TBL] [Abstract][Full Text] [Related]
12. Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.
Duparc S; Chalon S; Miller S; Richardson N; Toovey S
Malar J; 2020 Mar; 19(1):111. PubMed ID: 32169086
[TBL] [Abstract][Full Text] [Related]
13. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
15. Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence.
Val F; Costa FT; King L; Brito-Sousa JD; Bassat Q; Monteiro WM; Siqueira AM; Luzzatto L; Lacerda MV
Future Microbiol; 2019 Oct; 14():1261-1279. PubMed ID: 31596137
[TBL] [Abstract][Full Text] [Related]
16. Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Baird JK
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30380095
[TBL] [Abstract][Full Text] [Related]
17. Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax.
Tan KR; Hwang J
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30137454
[No Abstract] [Full Text] [Related]
18. Tafenoquine for the treatment of
Llanos-Cuentas A; Manrrique P; Rosas-Aguirre A; Herrera S; Hsiang MS
Expert Opin Pharmacother; 2022 May; 23(7):759-768. PubMed ID: 35379070
[TBL] [Abstract][Full Text] [Related]
19. Tafenoquine: a toxicity overview.
Chu CS; Hwang J
Expert Opin Drug Saf; 2021 Mar; 20(3):349-362. PubMed ID: 33306921
[No Abstract] [Full Text] [Related]
20. Tafenoquine for
Sharma J; Gautam CS; Singh H; Singh J
Indian J Med Res; 2021 Jun; 154(6):797-805. PubMed ID: 35662084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
